Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.39 |
| ▸ | RXRB | P28702 | 6/20 | 0.39 |
| ▸ | RXRG | P48443 | 5/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.37 |
| ▸ | RARB | P10826 | 4/20 | 0.37 |
| ▸ | RARG | P13631 | 4/20 | 0.37 |
| ▸ | RARA | P10276 | 3/20 | 0.37 |
| ▸ | HNF4A | P41235 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821362 | 0.91 | RARB (0.35) | RXRARXRBRXRGCYP26A1RARB | |
| SCHEMBL2824872 | 0.86 | RXRA (0.40) | RXRARXRBRXRGCYP26A1RARB | |
| SCHEMBL2821029 | 0.84 | TBXAS1 (0.39) | TBXAS1 | |
| SCHEMBL2823157 | 0.83 | L3MBTL1 (0.45) | TBXAS1 | |
| SCHEMBL2819674 | 0.83 | TBXAS1 (0.43) | TBXAS1 | |
| SCHEMBL2820791 | 0.83 | KLKB1 (0.39) | TBXAS1 | |
| SCHEMBL2819515 | 0.82 | THRB (0.43) | CYP3A4 | |
| SCHEMBL2819276 | 0.82 | KLKB1 (0.41) | TBXAS1 | |
| SCHEMBL2821986 | 0.82 | TBXAS1 (0.42) | TBXAS1 | |
| SCHEMBL2822731 | 0.81 | RARA (0.36) | RXRARXRBRXRGCYP26A1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | claimed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | RXRA 17/4885RXRB 19/4885RXRG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.